Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study
Source : https://bmjopenrespres.bmj.com/content/10/1/e001607
Introduction Bronchodilators, including long-acting muscarinic antagonists (LAMA) and long-acting beta 2 agonists (LABA), are the main treatments for chronic obstructive pulmonary disease (COPD). The efficacy of triple therapy (inhaled corticosteroids/LAMA/LABA)...
Conclusions/Relevance: This study analyses not only the effects of triple therapy for mild-to-moderate COPD but also the adverse events. Triple therapy has been reported to be associated with a higher incidence of bacterial pneumonia than LAMA/LABA. It is possible that Japanese patients with COPD may be at a higher risk of developing...
A systematic review of behaviour change techniques in pharmacist-delivered self-management interventions towards patients with chronic obstructive pulmonary disease
Source : https://www.sciencedirect.com/science/article/abs/pii/S1551741123002565?via=ihub
The authors received no financial support for the research, authorship, and/or publication of this article. The datasets analysed during the study are available from the corresponding author on reasonable request....
Conclusions: Pharmacists have provided interventions towards improving health behaviours, especially on adherence and usage of inhaler devices for patients with COPD. Future self-management interventions should be designed using the identified BCTs for the improvement of COPD self-management and disease outcomes.
Inhaled Corticosteroids and Bronchiectasis: Friend or Foe? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37176763/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Many issues have yet to be resolved, such as the effect of comorbidities, the dose of ICs, the ideal cut-off point to define peripheral eosinophilia in this context as an indicator of which patients to treat, and the potential deleterious effect of ICs on bronchiectasis patients with CBI due to PPM. It is to be hoped that ongoing...
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
The American Thoracic Society (ATS) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend prescribing dual therapy (LAMA/LABA) for COPD patients with low-exacerbation risk and reserving triple therapy...
Conclusion: These real-world results support ATS and GOLD recommendations for treating low-exacerbation risk COPD patients with dual bronchodilators and TT for more severe, higher-exacerbation risk COPD patients.
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
Chronic obstructive pulmonary disease (COPD) can be treated with a combination of two bronchodilators, such as umeclidinium/vilanterol (UMEC/VI), a long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA) administered once daily, or a...
Conclusion: At 12 months post-treatment initiation, once-daily UMEC/VI was superior to twice-daily ICS/LABA in medication adherence among patients with COPD without exacerbations in the previous year, newly initiating dual maintenance therapy in England. The finding was consistent at 6, 18, and 24 months.